 NEW YORK and VIENNA, Austria, Dec. 11, 2020 GLOBE NEWSWIRE -- HOOKIPA Pharma Inc. Nasdaq: HOOK, a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,910,000 shares of its common stock and 2,978 shares of its Series A convertible preferred stock the Offering. The public offering price of each share of common stock is 11.75 and the public offering price of each share of Series A preferred stock is 11,750 each share of Series A preferred stock is convertible into 1,000 shares of common stock. The gross proceeds to HOOKIPA from this offering are expected to be approximately 80.9 million before deducting underwriting discounts and commissions and other offering expenses, which includes the exercise in full of the underwriters option to purchase 510,000 additional shares. All of the securities in the Offering were sold by HOOKIPA. 